Save up -80% on Bivalirudin
Note: this is a drug discount program, not an insurance plan.
Price of Bivalirudin
Angiomax 250 mg vial
* price without discount in nearest pharmacy. Price may vary.
We offer free Bivalirudin coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your coupon in most local pharmacies to get a discount on Bivalirudin. Claim your prescription drug card now!
Bivalirudin volume of distribution
What is Bivalirudin
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Bivalirudin mechanism of action
Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.
Dosage forms of Bivalirudin
|Injection, powder, lyophilized, for solution||intravenous||250 mg/1|
|Powder for solution||intravenous||250 mg|
The Medicines Company
Humans and other mammals
Indication of Bivalirudin
For treatment of heparin-induced thrombocytopenia and for the
prevention of thrombosis. Bivalirudin is indicated for use in
patients undergoing percutaneous coronary intervention (PCI), in
patients at moderate to high risk acute coronary syndromes due to
unstable angina or non-ST segment elevation in whom a PCI is planned.
Toxicity of Bivalirudin
Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.
Disclaimer: before buying a Bivalirudin on prescription, consult your health care provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.